REUTERS - U.S. drug regulators have for the first time approved a therapy that uses cells of human blood from the placenta and the umbilical cord to treat people with blood-forming disorders or cancer.
The Food and Drug Administration on Thursday licensed Hemacord, manufactured by the New York Blood Center (NYBC), a therapy that contains self-recreating cells similar to stem cells from human cord blood.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
